{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T19:09:58Z","timestamp":1781291398961,"version":"3.54.1"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,11,1]],"date-time":"2023-11-01T00:00:00Z","timestamp":1698796800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,12,19]],"date-time":"2023-12-19T00:00:00Z","timestamp":1702944000000},"content-version":"vor","delay-in-days":48,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100012550","name":"Nemzeti Kutat\u00e1si, Fejleszt\u00e9si \u00e9s Innovaci\u00f3s Alap","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012550","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["I2872-B28"],"award-info":[{"award-number":["I2872-B28"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["FWF I3522"],"award-info":[{"award-number":["FWF I3522"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["I4677"],"award-info":[{"award-number":["I4677"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002428","name":"Austrian Science Fund","doi-asserted-by":"publisher","award":["I3977"],"award-info":[{"award-number":["I3977"]}],"id":[{"id":"10.13039\/501100002428","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018818","name":"National Research, Development and Innovation Office","doi-asserted-by":"publisher","award":["\\u00DANKP-22-4-II-SE-11"],"award-info":[{"award-number":["\\u00DANKP-22-4-II-SE-11"]}],"id":[{"id":"10.13039\/501100018818","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lungcancerjournal.info","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Lung Cancer"],"published-print":{"date-parts":[[2023,11]]},"DOI":"10.1016\/j.lungcan.2023.107360","type":"journal-article","created":{"date-parts":[[2023,9,7]],"date-time":"2023-09-07T11:51:43Z","timestamp":1694087503000},"page":"107360","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"special_numbering":"C","title":["Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma"],"prefix":"10.1016","volume":"185","author":[{"given":"Paul","family":"Stockhammer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Baumeister","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Till","family":"Ploenes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Bonella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dirk","family":"Theegarten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Dome","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Pirker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Walter","family":"Berger","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luca","family":"Heged\u00fcs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcell","family":"Baranyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Schuler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sophie","family":"Deshayes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Servet","family":"B\u00f6l\u00fckbas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Aigner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Blanquart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Balazs","family":"Heged\u00fcs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.lungcan.2023.107360_b0005","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1007\/s004080000075","article-title":"The pleura in health and disease","volume":"179","author":"Jones","year":"2001","journal-title":"Lung"},{"issue":"9564","key":"10.1016\/j.lungcan.2023.107360_b0010","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/S0140-6736(07)60412-7","article-title":"Ecological association between asbestos-related diseases and historical asbestos consumption: an international analysis","volume":"369","author":"Lin","year":"2007","journal-title":"Lancet"},{"issue":"10272","key":"10.1016\/j.lungcan.2023.107360_b0015","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/S0140-6736(20)32714-8","article-title":"First-line nivolumab plus ipilimumab in unresectable malignant pleural mesothelioma (CheckMate 743): a multicentre, randomised, open-label, phase 3 trial","volume":"397","author":"Baas","year":"2021","journal-title":"Lancet"},{"key":"10.1016\/j.lungcan.2023.107360_b0020","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2022.916839","article-title":"Novel Insights Into Mesothelioma Therapy: Emerging Avenues and Future Prospects","volume":"12","author":"Kuryk","year":"2022","journal-title":"Front. Oncol."},{"issue":"8","key":"10.1016\/j.lungcan.2023.107360_b0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrc.2017.42","article-title":"Novel insights into mesothelioma biology and implications for therapy","volume":"17","author":"Yap","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2023.107360_b0030","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1038\/nrgastro.2013.120","article-title":"Mucins in pancreatic cancer and its microenvironment","volume":"10","author":"Kaur","year":"2013","journal-title":"Nat. Rev. Gastroenterol. Hepatol."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107360_b0035","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22126567","article-title":"MUC1: Structure, Function, and Clinic Application in Epithelial Cancers","volume":"22","author":"Chen","year":"2021","journal-title":"Int. J. Mol. Sci."},{"issue":"6","key":"10.1016\/j.lungcan.2023.107360_b0040","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1016\/j.molmed.2014.02.007","article-title":"MUC1: a multifaceted oncoprotein with a key role in cancer progression","volume":"20","author":"Nath","year":"2014","journal-title":"Trends Mol. Med."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107360_b0045","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1309\/9R6673QEC06D86Y4","article-title":"Differential expression of MUC1, MUC2, and MUC5AC in carcinomas of various sites: an immunohistochemical study","volume":"122","author":"Lau","year":"2004","journal-title":"Am. J. Clin. Pathol."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107360_b0050","doi-asserted-by":"crossref","DOI":"10.3892\/ijo.2021.5248","article-title":"MUC1 is an oncoprotein with a significant role in apoptosis (Review)","volume":"59","author":"Supruniuk","year":"2021","journal-title":"Int. J. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107360_b0055","doi-asserted-by":"crossref","first-page":"776","DOI":"10.3892\/ol.2017.6254","article-title":"Pre-operative evaluation of circulating KL-6 levels as a biomarker for epithelial ovarian carcinoma and its correlation with tumor MUC1 expression","volume":"14","author":"Sato","year":"2017","journal-title":"Oncol. Lett."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107360_b0060","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1002\/1097-0142(19910801)68:3<574::AID-CNCR2820680322>3.0.CO;2-B","article-title":"The value of the tumor marker CA 15\u20133 in diagnosing and monitoring breast cancer. A comparative study with carcinoembryonic antigen","volume":"68","author":"Safi","year":"1991","journal-title":"Cancer"},{"issue":"3","key":"10.1016\/j.lungcan.2023.107360_b0065","first-page":"203","article-title":"Detection of soluble tumor-associated antigens in sera and effusions using novel monoclonal antibodies, KL-3 and KL-6, against lung adenocarcinoma","volume":"18","author":"Kohno","year":"1988","journal-title":"Jpn. J. Clin. Oncol."},{"key":"10.1016\/j.lungcan.2023.107360_b0070","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1002\/ijc.2910570717","article-title":"Difference in sero-diagnostic values among KL-6-associated mucins classified as cluster 9","volume":"8","author":"Kohno","year":"1994","journal-title":"Int. J. Cancer Suppl."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107360_b0075","doi-asserted-by":"crossref","first-page":"1276","DOI":"10.1378\/chest.109.5.1276","article-title":"Serum KL-6 for the evaluation of active pneumonitis in pulmonary sarcoidosis","volume":"109","author":"Kobayashi","year":"1996","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.lungcan.2023.107360_b0080","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1378\/chest.108.2.311","article-title":"KL-6: a serum marker for interstitial pneumonia","volume":"108","author":"Kobayashi","year":"1995","journal-title":"Chest"},{"key":"10.1016\/j.lungcan.2023.107360_b0085","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.trim.2018.10.006","article-title":"Changes in serum KL-6 levels are associated with the development of chronic lung allograft dysfunction in lung transplant recipients","volume":"52","author":"Bessa","year":"2019","journal-title":"Transpl. Immunol."},{"issue":"10","key":"10.1016\/j.lungcan.2023.107360_b0090","doi-asserted-by":"crossref","first-page":"2216","DOI":"10.1002\/jmv.26087","article-title":"Serum KL-6 concentrations as a novel biomarker of severe COVID-19","volume":"92","author":"d'Alessandro","year":"2020","journal-title":"J. Med. Virol."},{"issue":"34","key":"10.1016\/j.lungcan.2023.107360_b0095","doi-asserted-by":"crossref","first-page":"12171","DOI":"10.3748\/wjg.v20.i34.12171","article-title":"Inhibition of KL-6\/MUC1 glycosylation limits aggressive progression of pancreatic cancer","volume":"20","author":"Xu","year":"2014","journal-title":"World J. Gastroenterol."},{"issue":"23\u201324","key":"10.1016\/j.lungcan.2023.107360_b0100","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1016\/j.lfs.2011.03.021","article-title":"Expression of KL-6\/MUC1 in pancreatic ductal carcinoma and its potential relationship with beta-catenin in tumor progression","volume":"88","author":"Xu","year":"2011","journal-title":"Life Sci."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107360_b0105","first-page":"371","article-title":"Expression of KL-6\/MUC1 in pancreatic cancer tissues and its potential involvement in tumor metastasis","volume":"26","author":"Xu","year":"2011","journal-title":"Oncol. Rep."},{"issue":"1\u20134","key":"10.1016\/j.lungcan.2023.107360_b0110","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1016\/j.bbrc.2018.11.016","article-title":"MUC1\/KL-6 expression confers an aggressive phenotype upon myeloma cells","volume":"507","author":"Endo","year":"2018","journal-title":"Biochem. Biophys. Res. Commun."},{"issue":"9","key":"10.1016\/j.lungcan.2023.107360_b0115","doi-asserted-by":"crossref","first-page":"1562","DOI":"10.1038\/sj.bjc.6604340","article-title":"Overexpression and altered glycosylation of MUC1 in malignant mesothelioma","volume":"98","author":"Creaney","year":"2008","journal-title":"Br. J. Cancer"},{"issue":"5","key":"10.1016\/j.lungcan.2023.107360_b0120","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1183\/09031936.00160210","article-title":"Recognition of pleural mesothelioma by mucin-1(950\u2013958)\/human leukocyte antigen A*0201-specific CD8+ T-cells","volume":"38","author":"Roulois","year":"2011","journal-title":"Eur. Respir. J."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107360_b0125","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.canlet.2013.07.020","article-title":"Enhancement of in vitro cell motility and invasiveness of human malignant pleural mesothelioma cells through the HIF-1alpha-MUC1 pathway","volume":"339","author":"Goudarzi","year":"2013","journal-title":"Cancer Lett."},{"issue":"2","key":"10.1016\/j.lungcan.2023.107360_b0130","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1002\/ijc.26007","article-title":"Krebs von den Lungen-6 (KL-6) is a prognostic biomarker in patients with surgically resected nonsmall cell lung cancer","volume":"130","author":"Tanaka","year":"2012","journal-title":"Int. J. Cancer"},{"issue":"10","key":"10.1016\/j.lungcan.2023.107360_b0135","first-page":"4069","article-title":"Evaluation of serum KL-6, a mucin-like glycoprotein, as a tumor marker for breast cancer","volume":"6","author":"Ogawa","year":"2000","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107360_b0140","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.hepres.2005.06.011","article-title":"Serum KL-6 as a novel tumor marker for hepatocellular carcinoma in hepatitis C virus infected patients","volume":"33","author":"Kurosaki","year":"2005","journal-title":"Hepatol. Res."},{"issue":"11","key":"10.1016\/j.lungcan.2023.107360_b0145","doi-asserted-by":"crossref","first-page":"3780","DOI":"10.1158\/0008-5472.CAN-03-1460","article-title":"Genome-wide profiling of papillary thyroid cancer identifies MUC1 as an independent prognostic marker","volume":"64","author":"Wreesmann","year":"2004","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107360_b0150","doi-asserted-by":"crossref","first-page":"20114","DOI":"10.1038\/s41598-020-76641-x","article-title":"Multicellular contractility contributes to the emergence of mesothelioma nodules","volume":"10","author":"Tarnoki-Zach","year":"2020","journal-title":"Sci. Rep."},{"issue":"14","key":"10.1016\/j.lungcan.2023.107360_b0155","doi-asserted-by":"crossref","first-page":"3819","DOI":"10.1158\/1078-0432.CCR-19-3573","article-title":"Telomerase Reverse Transcriptase Promoter Mutations Identify a Genomically Defined and Highly Aggressive Human Pleural Mesothelioma Subgroup","volume":"26","author":"Pirker","year":"2020","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.lungcan.2023.107360_b0160","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1016\/j.lungcan.2020.04.002","article-title":"HDAC inhibition synergizes with ALK inhibitors to overcome resistance in a novel ALK mutated lung adenocarcinoma model","volume":"144","author":"Stockhammer","year":"2020","journal-title":"Lung Cancer"},{"key":"10.1016\/j.lungcan.2023.107360_b0165","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.lungcan.2023.03.003","article-title":"TROP2 expression and SN38 antitumor activity in malignant pleural mesothelioma cells provide a rationale for antibody-drug conjugate therapy","volume":"178","author":"Hegedus","year":"2023","journal-title":"Lung Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2023.107360_b0170","doi-asserted-by":"crossref","first-page":"2818","DOI":"10.1021\/pr4012377","article-title":"Targeted proteomics pipeline reveals potential biomarkers for the diagnosis of metastatic lung cancer in pleural effusion","volume":"13","author":"Chen","year":"2014","journal-title":"J. Proteome Res."},{"issue":"4","key":"10.1016\/j.lungcan.2023.107360_b0175","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1159\/000348499","article-title":"Diagnostic usefulness of MUC1 and MUC4 for distinguishing between metastatic adenocarcinoma cells and reactive mesothelial cells in effusion cell blocks","volume":"57","author":"Cho","year":"2013","journal-title":"Acta Cytol."},{"issue":"12","key":"10.1016\/j.lungcan.2023.107360_b0180","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1093\/qjmed\/hcu130","article-title":"Diagnostic value of MUC1 and EpCAM mRNA as tumor markers in differentiating benign from malignant pleural effusion","volume":"107","author":"Sun","year":"2014","journal-title":"QJM"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107360_b0185","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.chest.2016.12.004","article-title":"Malignant Mesothelioma Biomarkers: From Discovery to Use in Clinical Practice for Diagnosis, Monitoring, Screening, and Treatment","volume":"152","author":"Creaney","year":"2017","journal-title":"Chest"},{"issue":"34","key":"10.1016\/j.lungcan.2023.107360_b0190","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin Immunotherapy for Cancer: Ready for Prime Time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107360_b0195","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1186\/1476-4598-5-50","article-title":"Mesothelin-MUC16 binding is a high affinity, N-glycan dependent interaction that facilitates peritoneal metastasis of ovarian tumors","volume":"5","author":"Gubbels","year":"2006","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.lungcan.2023.107360_b0200","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.ctrv.2015.05.001","article-title":"The established and future biomarkers of malignant pleural mesothelioma","volume":"41","author":"Panou","year":"2015","journal-title":"Cancer Treat. Rev."},{"key":"10.1016\/j.lungcan.2023.107360_b0205","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.lungcan.2019.11.013","article-title":"Detection of TGF-beta in pleural effusions for diagnosis and prognostic stratification of malignant pleural mesothelioma","volume":"139","author":"Stockhammer","year":"2020","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.lungcan.2023.107360_b0210","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1007\/s11748-016-0706-4","article-title":"Prognostic significance of preoperative serum Krebs von den Lungen-6 level in non-small cell lung cancer","volume":"64","author":"Tomita","year":"2016","journal-title":"Gen. Thorac. Cardiovasc. Surg."},{"issue":"1","key":"10.1016\/j.lungcan.2023.107360_b0215","first-page":"107","article-title":"Expression and localization of MUC1, MUC2, MUC5AC and small intestinal mucin antigen in pancreatic tumors","volume":"24","author":"Yamasaki","year":"2004","journal-title":"Int. J. Oncol."},{"key":"10.1016\/j.lungcan.2023.107360_b0220","doi-asserted-by":"crossref","unstructured":"Bonotti, A., et al., Serum mesothelin, osteopontin and vimentin: useful markers for clinical monitoring of malignant pleural mesothelioma. Int J Biol Markers, 2017. 32(1): p. e126-e131.","DOI":"10.5301\/jbm.5000229"},{"issue":"1","key":"10.1016\/j.lungcan.2023.107360_b0225","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1111\/resp.12874","article-title":"Malignant pleural fluid from mesothelioma has potent biological activities","volume":"22","author":"Cheah","year":"2017","journal-title":"Respirology"},{"issue":"6","key":"10.1016\/j.lungcan.2023.107360_b0230","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1164\/rccm.201203-0465PP","article-title":"Malignant pleural effusion: tumor-host interactions unleashed","volume":"186","author":"Stathopoulos","year":"2012","journal-title":"Am. J. Respir. Crit. Care Med."},{"issue":"3","key":"10.1016\/j.lungcan.2023.107360_b0235","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1183\/09031936.00063109","article-title":"Guidelines of the European Respiratory Society and the European Society of Thoracic Surgeons for the management of malignant pleural mesothelioma","volume":"35","author":"Scherpereel","year":"2010","journal-title":"Eur. Respir. J."},{"issue":"5","key":"10.1016\/j.lungcan.2023.107360_b0240","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1111\/crj.13010","article-title":"Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy","volume":"13","author":"Murthy","year":"2019","journal-title":"Clin. Respir. J."},{"issue":"17","key":"10.1016\/j.lungcan.2023.107360_b0245","doi-asserted-by":"crossref","first-page":"5323","DOI":"10.1158\/1078-0432.CCR-09-0737","article-title":"The prioritization of cancer antigens: a national cancer institute pilot project for the acceleration of translational research","volume":"15","author":"Cheever","year":"2009","journal-title":"Clin. Cancer Res."}],"container-title":["Lung Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300898X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S016950022300898X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T04:08:49Z","timestamp":1778731729000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S016950022300898X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,11]]},"references-count":49,"alternative-id":["S016950022300898X"],"URL":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107360","relation":{},"ISSN":["0169-5002"],"issn-type":[{"value":"0169-5002","type":"print"}],"subject":[],"published":{"date-parts":[[2023,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Krebs von den Lungen 6 (KL-6) is a novel diagnostic and prognostic biomarker in pleural mesothelioma","name":"articletitle","label":"Article Title"},{"value":"Lung Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.lungcan.2023.107360","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"107360"}}